Dexcom, a global leader in glucose biosensing technology, announced the official appointment of Glenn Boehnlein to its Board of Directors today. This high-profile appointment thus speeds up the company’s strategic growth initiatives and amplifies its long-term market impact. Boehnlein has more than 20 years of executive experience in the medical technology industry. Additionally, he has expertise in capital allocation, strategic M&A, financial leadership, and operational excellence.
Most recently, Boehnlein served as Vise President and Chief Financial Officer of Stryker Corporation. He guided the global medical device leader through significant growth periods during his tenure as an executive. Plus, he has headed important innovation programs and pushed for international market penetration. “His experience in MedTech corporate governance is a great asset to the company.”
This summer, Dexcom embarked on an extensive search for an independent director. The leadership team specifically sought a candidate possessing deep MedTech experience alongside proven global scale capabilities. Therefore, Boehnlein’s extensive background at one of the world’s premier healthcare organizations aligned perfectly with the long-range strategy of Dexcom.
“Earlier this summer, we launched a search for a new independent director with deep MedTech experience and a proven track record of global scale,” said Jake Leach, president and CEO at Dexcom. “Glenn’s extensive leadership at one of the most respected MedTech companies in the world makes him a perfect fit. During his time at Stryker, he helped the company deliver consistently strong organic revenue growth, earnings performance, and free cash flow generation. As we execute against our newly announced long-range plan, his perspective and expertise will be an invaluable asset to our Board.”
Accelerating Strategic Expansion Across Diabetes and Metabolic Health
Transitioning into his new governance role, Boehnlein will collaborate directly with executive leaders to guide financial growth. His strategic oversight will help steer upcoming corporate developments across glucose monitoring and metabolic healthcare portfolios.
“I am honored to join the Dexcom Board during such an exciting period of innovation and growth for the company,” said Boehnlein. “I look forward to working with the Board and management team as the company continues to expand its impact across diabetes and metabolic health.”
Meanwhile, Dexcom continues prioritizing continuous glucose monitoring breakthroughs nationwide. By adding seasoned operational leadership, Dexcom positions itself to deliver sustainable long-term value for shareholders and patients.
For more stories on technology leaders shaping the future of enterprise solutions, visit our CXO Insiders.
News Source: Businesswire
